[生物医药论文精品]不同分子量壳寡糖对高脂糖尿病大鼠的果糖胺和血脂的影响

1不同分子量壳寡糖对高脂糖尿病大鼠的果糖胺和血脂的影响摘要目的探讨不同分子量壳寡糖对糖尿病大鼠的作用机制。方法WISTAR大鼠采用高脂高糖饮食同时腹腔注射链脲佐菌素复制糖尿病大鼠模型。将动物随机分为正常对照组、模型组、阳性对照和药物治疗组。给药两周后进行糖耐量试验。四周后处死大鼠取血清测定血糖、果糖胺和血脂各项指标。结果与正常组比较，模型组血糖、果糖胺水平明显升高（P005）。G16277表1。表1壳寡糖对DM大鼠糖耐量的影响（XS）TABLE1EFFCTOFCOSONGLUCOSETOLERANCEINDIABETICRATS（XS）GROUPNGLUCOSEA74MMOLL1A75AUC0H05H1H2HNORMAL10412A76026554A76024708A76139572A761072394A76254MODEL102126A767523319A765472944A768092156A7645710954A762180ACARBOSE10676A774012766A7710232459A779801295A773108238A7726571700LOWDOSE151037A773953089A778302611A7711161950A776629474A7731461700HIGHDOSE12699A772372785A778882439A776661474A776568267A7720583000COS81445A778313061A779133135A77506197A7776510456A772138VSNORMALP005）。G16277表3。表3壳寡糖对DM大鼠血脂的影响（MMOLL1,XS）TABLE3EFFCTOFCOSONSERUMLIPOPROTEININDIABETICRATS（MMOLL，XS）GROUPTCTGHDLA81A82A82NORMAL145A83054046A83028208029A84A85A86A87A83A84A85A88A87MODEL361A83167295A83036054014A89A85A86A89A83A84A85A90A91ACARBOSE201A92059097A92080140A92032A93A94A95A96A92A93A94A951700LOWDOSE169A92035156A92054134A92035A93A94A97A98A92A93A94A99A961700HIGHDOSE148A92048081A92070101A92016A100A94A100A96A92A93A94A95A973000COS192A92034100A92035114A92056A100A94A95A92A93A94A96A9654讨论本G4466验G3324高脂高糖饮食G3534G11796上腹腔注射STZ复制大鼠DM模型，模型大鼠血糖、果糖胺水平升高，血脂G2559量G1075明显变化，G16840明高脂糖尿病模型G17908模G6116G2163。G3324模型G3534G11796上灌G13975治疗，各治疗组血糖水平明显降低。G1866G10251700壳寡糖高剂量组（140MGKG1）降血糖G6940果G7380明显，低剂量组（70MGKG1）降糖G6940果G8437G1055。G1186分子量分G75243000壳寡糖组血糖降低与同剂量1700组G7092明显G5058G5334。G16840明壳寡糖具有G980定的降血糖作用，G13792且这种作用具有剂量依赖性。G6564G12046临G5214G5224用壳寡糖降糖时G5224注G5859G1363用剂量，大鼠的日用剂量为140MGKG1时降糖G6940果G7380明显，本G11752G12362选用的两种分子量壳寡糖G3324降糖方G19766G7092明显G5058G5334。壳寡糖治疗四周后空腹血糖有G991降G17247G2195，高剂量组糖耐量显G14891改善，各给药组果糖胺水平明显降低。果糖胺G2460称糖化血清蛋白，G4439G7171血清G1025的各种蛋白G17148与葡萄糖G2469G10995缓G5942G19762酶G1431G2465G5224的G1147物，G13792血清G1025G235670G5050G2503的白蛋白代谢较G12295定，半G15940G7411为19D，G6937血清G1025果糖胺的G2559量G14033G3827G2465G7156前23周的血糖平G3355水平，且不G2475饮食、药物G2462血糖G8886动的G5190G6212，G7171G16792G1284降糖方G7708G1025G7411血糖水平的G4470G16278依G64665。本G11752G12362G1025各组G19400果糖胺的G5058G5334且G2588G10628剂量G6940G5224G1863G13007，进G980G8505证明G1114壳寡糖的降糖作用G2462剂量G1863G13007。2型糖尿病G2469G10995血脂代谢G2469G10995紊乱的G2419G3252可G14033G7171G980方G19766G1319G1881G14020G4719素分G8864不G17287，G13792G11464G6521G4560G14280血脂代谢紊乱，G13792G2490G980方G19766可G14033G7171血糖G8999度G17819高，机G1319不G14033分G16311G2045用，G17819度合G6116血脂G6564G1391G14033量，G1363患者食量G3698G2164，机G1319G1881血脂G3698G21646。G17829G5192G7481游离脂肪酸作为脂G8614性的G18337G16213标G5547，G1866G5859G1053G17246G7481G17246引G1166G1863注。高游离脂肪酸血G11163G7171脂肪组G13467（G1039G16213G7171G1881G14051脂肪）G14020G4719素G6281G6251后大量分G16311的后果，G13792G980G7098游离脂肪酸G8999度升高，G17819G3822的游离脂肪酸可G17902G17819G3822种G17896G5464G4560G14280G14020G4719素G6281G6251的G2469G109957。由表3可G11487G19981700壳寡糖两G1022剂量组的游离脂肪酸与模型组G11468比G18129具有显G14891性G5058G5334，且具有剂量G6940G5224。本G11752G12362壳寡糖不G1177G14033改善糖尿病大鼠的G980G14336G10378G1929，G3698G2164G1319G18337，G13792且G17836G14033显G14891降低DM大鼠的TC、TG、FFAG2559量，显G14891升高HDLCG2559量，证明壳寡糖G3324降低血糖的同时G14033改善脂代谢紊乱。本G11752G12362G1025G3324降脂方G197663000壳寡糖组作用不显G14891。1700壳寡糖组两种剂量降血脂G6940果与模型组G11468比G18129有显G14891性G5058G5334。G6564G12046壳寡糖降血脂作用与G1866分子量和结G7512有G1863。本G11752G12362G6564G12046壳寡糖作为药用G6122保G1593食G2709，分子量1700、日用剂量140MGKG1适合高脂糖尿病大鼠，G14033起到降低血糖、调节血脂的作用。参考文献1MIURAT,USAMIM,ETALHYPOGLYCEMICANDHYPOLIPIDEMICEFFECTOFCHITOSANINNORMALANDNEONATALSTREPTOZOTOCININDUCEDIABETICMICEJBIOLOGICALANDPHARMACEUTICALBULLETIN,1995,181116232G4600行G4451，G2568G2203，G5441G3290，G12573低分子壳G13870糖对糖尿病大鼠血糖、血脂G2559量的G5445G2721JG1025G3281G13781G5192学杂G5547，2005，255415433乔新惠,李邦良,宋岚G11014壳低G13870糖对NODG4579鼠降血糖作用G16278G4531J南华大学学G6265医学版，2003，313260261，2714郑铁G10995，王亚娜，宗爱萍龙G15442壳G13870糖G5190预后糖尿病G4579鼠血糖和糖耐量的变化JG1025G3281临G5214康复，2006，10（31）67695肖洪广，黄泽红，刘汉欣，G12573糖化血红蛋白、果糖胺与葡萄糖水平G33242型糖尿病诊治G1025的G5224用JG10628代临G5214医学G10995物工程学杂G5547，2005，11（2）14014